Lumimeds: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://lumimeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   ““Doctors frequently recommend Compounded Tirzepatide or Compounded Semaglutide, both of which are GLP-1 agonists with the same active ingredient as the brand name medications.””

2. 2

   ““GLP-1 Injections contain GLP-1, which mimics a naturally occurring hormone in the body. This is the same active ingredient used in brand name GLP-1 weight-loss medications. GLP-1 was FDA-approved in 2017 . . . . It was FDA-approved in 2021 for weight loss.””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

lumimeds.com returned a live storefront when we checked in August 2026, with weight-loss and longevity programmes, a published pricing page and a referral scheme. We did not review every page on the site.

The error FDA cited here is one a shopper is likely to repeat, because the copy taught it. An approval belongs to a specific product made by a specific manufacturer at a specific strength — it does not belong to a molecule, and it certainly does not belong to "GLP-1" as a category. Once you accept that a whole class was approved in 2017, every vial containing anything in that class inherits the credential, and price becomes the only thing left to compare. That is precisely the inference FDA objected to. Nothing in the letter says the medication does not work; it says the approval being invoked was never granted to what is in the compounded vial. When you are comparing subscriptions, check what the specific product is, not what the class is.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Lumimeds failed to respond.